[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-INNOSUP-2018-2020Pillar: Industrial LeadershipOpening Date: Deadline: Wed, 13 Mar 2019 17:00:00 (Brussels local time)Modification Date: Mon, 9 Apr 2018Latest information: Please note that the deadline for submissions of stage 2 proposals has been postponed to 11 October 2018. Applicants to stage 1 (27 proposals were received)will be informed about the result of the evaluation of their proposals within the normal timeframe.

A gene therapy for the rare disease spinal muscular atrophy could hit the U.S. market next year. If it does, the treatment will likely be sold by Novartis, not its developer, AveXis, thanks to a deal announced early this morning.

Novartis has agreed to buy AveXis (NASDAQ: AVXS) and its experimental SMA gene therapy AVXS-101 for $218 per share in cash, or $8.7 billion. The deal represents a whopping 88 percent premium to AveXis’s $119.60 closing price on April 6, and the price could jump higher, to $225 per share, if the deal doesn’t close by July 6. AveXis… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

‘Global Pharmaceutical & Biotechnology Environmental Monitoring Market’ contains all the necessary data and serve up complete guidance to the readers and competitors of Pharmaceutical & Biotechnology Environmental Monitoring market. It gives an accurate study of Pharmaceutical & Biotechnology …

Fmr Llc decreased its stake in Puma Biotechnology Inc (PBYI) by 19.2% based on its latest 2017Q4 regulatory filing with the SEC. Fmr Llc sold 405,816 shares as the company’s stock declined 33.20% with the market. The institutional investor held 1.71M shares of the major pharmaceuticals company at …

Prince Adam, is that you?

A few weeks ago 26-year-old Jeffrey Kendall from Torrington, Connecticut, shared a personal transformation photo to Reddit. The pics showed a significant change in Kendall’s appearance as he lost 70 pounds over the course of two years.

reddit.com

reddit.com

reddit.com

reddit.com

Many of the comments were about his hair, which is utterly amazing, and his uncanny resemblance to a Disney prince. He even had some fun with the concept by striking a Prince Adam pose on his personal Instagram.

Disney / Instagram: @jeffk8991

Kendall’s transformation journey is truly inspiring, but it certainly wasn’t easy.

Instagram: @jeffk8991

“I reached a new low in health both mentally and physically. My mom was coming home from a rehabilitation center after having suffered a traumatic brain injury seven months prior. My world was filled with emotion as I felt I sat idly by. My friend also happened to be motivated at the time and got me committed to my first of many workouts to come.”

Jeffrey Kendall

The process was slow and steady. I started with doing pushups and going for walks. The walks became jogs and soon I found workouts on YouTube to add to my routine. I adjusted my diet and counted calories. I tried to live a life of moderation and hold myself in a manner of the person I wanted to be.

There’s always some hunger and motivation challenges that with these things but I was never too strict on my diet and my appetite adjusted with time. As for motivation, with the emotion surrounding my mom, it made motivation for workouts much easier to find.

Provided

He added that he hopes people can take something postive from his experience. He plans to keep moving forward, and is looking to pursue modeling in the future. “I hope people can have a good day. I hope they can appreciate the moment and find happiness in their lives. I hope people will find love for each other in this ever-growing divisive world. My plan is to continue the pursuit of happiness.”

Instagram: @melacrylic

Oh, and is case you were wondering about his hair routine – Kendall is mindful and tries not to damage it, he also conditions every day, and washes every five to seven days.

😉😉😉😉

instagram.com

A late-stage clinical trial testing the combination of a Merck cancer treatment and a new type of cancer drug developed by Incyte has failed, dealing a blow to a new drug class that many hoped would expand the reach of cancer immunotherapy.

The Phase 3 study in melanoma tested the FDA-approved Merck (NYSE: MRK) cancer drug pembrolizumab (Keytruda) in combination with epacadostat, which was developed by Wilmington, DE-based Incyte (NASDAQ: INCY). The companies said Friday that an external review of the Phase 3 data concluded that compared to those treated with the Merck drug alone, the combination treatment… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

BioCrossroads, Indiana’s public-private initiative to grow the state’s life sciences sector, has a new report highlighting the industry’s economic activity in 2017 based on data from Indiana University.

According to the report, Indiana’s life sciences sector continues to expand in a couple of key areas, including the number of companies created, the number of new products receiving FDA approval, and the overall impact of the sector on the state’s economy.

Brian Stemme, BioCrossroads’ project director, says he’s excited about what the report reveals: Steady growth and significant expertise across the life sciences industry, whether it’s in pharmaceuticals, medical devices, agricultural… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesOpening Date: Deadline: Tue, 4 Sep 2018 17:00:00 (Brussels local time)Modification Date: Fri, 6 Apr 2018Latest information:

Normal
0

false
false
false

EN-GB
X-NONE
X-NONE

MicrosoftInternetExplorer4

/* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0cm 5.4pt 0cm 5.

Three weeks after disclosing a $55 million funding round, upstart anti-aging company Unity Biotechnology Inc. wants another $85 million in an initial public offering. Zeroing in on “cellular senescence” – when cells stop dividing and secrete proteins believed to damage nearby healthy tissue …

Genetic testing services from companies such as Ancestry and 23andMe have risen in popularity in the past decade, attracting consumers who are eager to learn more about their lineage or risk of contracting certain types of disease.

But there are plenty of smaller players trying to carve out a following in this industry. Milwaukee-based GenoPalate is one of them. The two-year-old startup recently raised some seed funding to help it ramp up sales of its DNA testing service that analyzes customers’ genetic data in order to make suggestions about foods they should eat.

“We want to be the specialist in… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS